NRx Pharmaceuticals Outlines Potential Paths To Revenue And Profitability In 2025; New Shareholder Update Highlights Potential 2024 Revenue From HOPE Therapeutics-Branded Clinics, 2025 Revenue From Sales Of NRX-100 (IV Ketamine) Pending FDA Approval, And 2025 Revenue From NRX-101 For Suicidal Bipolar Depression And Akathisia

7/1/24 8:15:21 AM ET

Biotechnology: Pharmaceutical Preparations

Health Care

Get the next $NRXP alert in real time by email

Get the next $NRXP alert in real time by email

Chat with this insight

Save time and jump to the most important pieces.

Recent Analyst Ratings for
$NRXP

Date	Price Target	Rating	Analyst

More analyst ratings

$NRXP
Financials

Live finance-specific insights

NRx Pharmaceuticals, Inc. (NASDAQ: NRXP) to Report Second Quarter and Year to Date 2024 Financial Results on August 14, 2024
RADNOR, Pa., Aug. 13, 2024 /PRNewswire/ -- NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) ("NRx Pharmaceuticals", the "Company"), a clinical-stage biopharmaceutical company, today announced that it will release its second quarter and year to date 2024 financial results after the market closes on Wednesday, August 14, 2024, via press release, which will be available on the Company's website at https://ir.nrxpharma.com/. The Company will host a conference call to discuss the financial results as well as provide a corporate update at 4:30pm ET the same day. A live webcast of the confere
8/13/24 4:01:00 PM ET
$NRXP
Biotechnology: Pharmaceutical Preparations
Health Care
NRx Pharmaceuticals Eyes First Commercial Revenue in 2024, Announces Breakthroughs in Bi-Annual Milestone Update
HARRISON TOWNSHIP, MI / ACCESSWIRE / May 8, 2024 / NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) is a clinical-stage biopharmaceutical company developing therapeutics based on its NMDA platform for the treatment of central nervous system disorders, specifically suicidal bipolar depression, chronic pain and PTSD. NRXP is developing NRX-101, an FDA-designated investigational Breakthrough Therapy for suicidal treatment-resistant bipolar depression and chronic pain. NRXP has partnered with Alvogen Pharmaceuticals around the development and marketing of NRX-101 for the treatment of suicidal bipolar depression. NRX-101 additionally has the potential to act as a non-opioid treatment for chronic pain, as
5/8/24 9:55:00 AM ET
$NRXP
Biotechnology: Pharmaceutical Preparations
Health Care
NRx Pharmaceuticals, Inc. (Nasdaq:NRXP) to Report First Quarter 2024 Financial Results on May 14, 2024
RADNOR, Pa., May 7, 2024 /PRNewswire/ -- NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) ("NRx Pharmaceuticals", the "Company"), a clinical-stage biopharmaceutical company, today announced that it will release its first quarter 2024 financial results after the market closes on Tuesday, May 14, 2024, via press release, which will be available on the Company's website at https://ir.nrxpharma.com/. The Company will host a conference call to discuss the financial results as well as provide a corporate update at 4:30pm ET the same day. A live webcast of the conference call will be availabl
5/7/24 4:01:00 PM ET
$NRXP
Biotechnology: Pharmaceutical Preparations
Health Care

$NRXP
Press Releases

Fastest customizable press release news feed in the world

NRx Pharmaceuticals (NASDAQ:NRXP) Appoints Michael Abrams as Chief Financial Officer
Industry veteran with extensive experience in key areas of focusInterim-CFO Richard Narido to focus on HOPE Therapeutics acquisition opportunitiesWILMINGTON, Del., Nov. 18, 2024 /PRNewswire/ -- NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) ("NRx Pharmaceuticals", the "Company"), a clinical-stage biopharmaceutical company, today announced it has appointed Michael Abrams as its permanent Chief Financial Officer. Mr. Abrams succeeds Interim-CFO Richard Narido, who will continue to support the Company's financial function and other projects. "We are delighted to welcome Mike to the NRx
11/18/24 4:05:00 PM ET
$NRXP
Biotechnology: Pharmaceutical Preparations
Health Care
NRx Pharmaceuticals (NASDAQ:NRXP) Reports Third Quarter and Year to Date 2024 Financial Results and Provides Business Update
On track to file New Drug Applications (NDAs) for NRX-100 (IV Ketamine) in treating suicidal ideation in depression, including bipolar depression and NRX-101 (Oral D-Cycloserine/Lurasidone) for Accelerated Approval in bipolar depression with suicidality or akathisia by year end 2024 with 2025 PDUFA date forecast.HOPE Therapeutics acquiring Interventional Psychiatry Clinics; key to developing a best-in-class network of care to prevent suicide, continues to expect first revenue by year-end 2024.74% reduction in net operating losses compared to 3rd quarter 2023 with profitability forecast in 2025 from HOPE Therapeutics and from sales of medication.Management to host a conference call November 1
11/14/24 4:05:00 PM ET
$NRXP
Biotechnology: Pharmaceutical Preparations
Health Care
NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) Reschedules Conference Call to Discuss Third Quarter and Year to Date 2024 Financial Results to November 18, 2024
WILMINGTON, Del., Nov. 13, 2024 /PRNewswire/ -- NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) ("NRx Pharmaceuticals", the "Company"), a clinical-stage biopharmaceutical company, today announced that it will reschedule its third quarter and year to date 2024 results conference call to Monday November 18, 2024 at 4:30pm ET, to accommodate any additional corporate news. A live webcast of the conference call will be available on the Company's website at https://ir.nrxpharma.com/events. Participants that are unable to join the webcast can access the conference call via telephone by diali
11/13/24 8:03:00 AM ET
$NRXP
Biotechnology: Pharmaceutical Preparations
Health Care

NRx Pharmaceuticals Announces the Election of Janet Rehnquist to its Board of Directors
Former Inspector General, US Dept. of Health and Human ServicesFormer Assistant US Attorney for the Eastern District of VirginiaNationally recognized attorney in highly regulated industries; healthcare specialistRADNOR, Pa., Dec. 27, 2023 /PRNewswire/ -- NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) ("NRx Pharmaceuticals", the "Company"), a clinical-stage biopharmaceutical company today announced that Janet Rehnquist has been elected to the Company's Board of Directors where she will chair the compliance and the nominating committees. Ms. Rehnquist is an experienced healthcare lawye
12/27/23 6:48:00 AM ET
$NRXP
Biotechnology: Pharmaceutical Preparations
Health Care
NRx Pharmaceuticals Announces the Appointment of Carrie M. Carretta, PhD, APN-BC, AHN-BC, PMHNP, Senior Vice President of Clinical Development and Medical Affairs
Extensive global pharmaceutical leadership experience in clinical development, operations, and medical affairsFocused psychiatry practice expert in PTSD, Affective Disorders and SchizophreniaProven track record in research as an investigator and academic grant-funded researcher Visiting Scholar at Stanford University, Center for Precision Mental Health and WellnessFormer roles at Boehringer Ingelheim and Pendulum Therapeutics RADNOR, Pa., Dec. 5, 2022 /PRNewswire/ -- NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) ("NRx Pharmaceuticals", the "Company"), a clinical-stage central nervous system (CNS) biopharmaceutical company, today announced the appointment of Carrie M. Carretta, PhD, APN-BC, AHN-BC,
12/5/22 6:47:00 AM ET
$NRXP
Biotechnology: Pharmaceutical Preparations
Health Care
NRx Pharmaceuticals Announces the Appointment of Stephen Willard, Chief Executive Officer and Director
Extensive experience in Law, Finance, and Management of Public and Private Biotechnology CompaniesProven track record of creating value for shareholdersNational Science Board Presidential Appointee, 2018-2024Former roles at Federal Deposit Insurance Corporation (FDIC) and E*Trade FinancialRADNOR, Pa., July 13, 2022 /PRNewswire/ -- NRx Pharmaceuticals, Inc. (NASDAQ:NRXP): ("NRx Pharmaceuticals", or the "Company"), a clinical-stage biopharmaceutical company, today announced the appointment of Stephen Willard, as its Chief Executive Officer ("CEO") and a member of the Company's Board of Directors. The Company's interim CEO, Robert Besthof, will continue to support the Company and return to his
7/13/22 7:15:00 AM ET
$NRXP
Biotechnology: Pharmaceutical Preparations
Health Care

Chat with this insight

Recent Analyst Ratings for
$NRXP

$NRXP
Financials

Live finance-specific insights

NRx Pharmaceuticals, Inc. (NASDAQ: NRXP) to Report Second Quarter and Year to Date 2024 Financial Results on August 14, 2024

NRx Pharmaceuticals Eyes First Commercial Revenue in 2024, Announces Breakthroughs in Bi-Annual Milestone Update

NRx Pharmaceuticals, Inc. (Nasdaq:NRXP) to Report First Quarter 2024 Financial Results on May 14, 2024

$NRXP
Insider Trading

Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

SEC Form 3 filed by new insider Abrams Michael S

SEC Form 3 filed by new insider Mcbride Dennis

SEC Form 3 filed by new insider Rehnquist Janet

$NRXP
Large Ownership Changes

This live feed shows all institutional transactions in real time.

SEC Form SC 13D filed by NRX Pharmaceuticals Inc.

SEC Form SC 13D/A filed by NRX Pharmaceuticals Inc. (Amendment)

SEC Form SC 13D filed by NRX Pharmaceuticals Inc.

$NRXP
Market Insights

Live Market Insights

NRx Pharmaceuticals To Proceed With Two New Drug Applications In 2024; NRX-101 Returned To Company For Filing

NRx Pharmaceuticals Publishes Shareholder Update Letter; Update Highlights Potential Implications Of The Company's Recent Activities At The Annual Meeting Of The American Society Of Clinical Psychopharmacology

$NRXP
SEC Filings

NRX Pharmaceuticals Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Leadership Update, Financial Statements and Exhibits

NRX Pharmaceuticals Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Regulation FD Disclosure, Financial Statements and Exhibits

SEC Form 10-Q filed by NRX Pharmaceuticals Inc.

$NRXP
Press Releases

Fastest customizable press release news feed in the world

NRx Pharmaceuticals (NASDAQ:NRXP) Appoints Michael Abrams as Chief Financial Officer

NRx Pharmaceuticals (NASDAQ:NRXP) Reports Third Quarter and Year to Date 2024 Financial Results and Provides Business Update

NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) Reschedules Conference Call to Discuss Third Quarter and Year to Date 2024 Financial Results to November 18, 2024

$NRXP
Leadership Updates

Live Leadership Updates

NRx Pharmaceuticals Announces the Election of Janet Rehnquist to its Board of Directors

NRx Pharmaceuticals Announces the Appointment of Carrie M. Carretta, PhD, APN-BC, AHN-BC, PMHNP, Senior Vice President of Clinical Development and Medical Affairs

NRx Pharmaceuticals Announces the Appointment of Stephen Willard, Chief Executive Officer and Director

Chat with this insight

Recent Analyst Ratings for $NRXP

$NRXP Financials

Live finance-specific insights

NRx Pharmaceuticals, Inc. (NASDAQ: NRXP) to Report Second Quarter and Year to Date 2024 Financial Results on August 14, 2024

NRx Pharmaceuticals Eyes First Commercial Revenue in 2024, Announces Breakthroughs in Bi-Annual Milestone Update

NRx Pharmaceuticals, Inc. (Nasdaq:NRXP) to Report First Quarter 2024 Financial Results on May 14, 2024

$NRXP Insider Trading

Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

SEC Form 3 filed by new insider Abrams Michael S

SEC Form 3 filed by new insider Mcbride Dennis

SEC Form 3 filed by new insider Rehnquist Janet

$NRXP Large Ownership Changes

This live feed shows all institutional transactions in real time.

SEC Form SC 13D filed by NRX Pharmaceuticals Inc.

SEC Form SC 13D/A filed by NRX Pharmaceuticals Inc. (Amendment)

SEC Form SC 13D filed by NRX Pharmaceuticals Inc.

$NRXP Market Insights

Live Market Insights

NRx Pharmaceuticals To Proceed With Two New Drug Applications In 2024; NRX-101 Returned To Company For Filing

NRx Pharmaceuticals Publishes Shareholder Update Letter; Update Highlights Potential Implications Of The Company's Recent Activities At The Annual Meeting Of The American Society Of Clinical Psychopharmacology

$NRXP SEC Filings

NRX Pharmaceuticals Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Leadership Update, Financial Statements and Exhibits

NRX Pharmaceuticals Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Regulation FD Disclosure, Financial Statements and Exhibits

SEC Form 10-Q filed by NRX Pharmaceuticals Inc.

$NRXP Press Releases

Fastest customizable press release news feed in the world

NRx Pharmaceuticals (NASDAQ:NRXP) Appoints Michael Abrams as Chief Financial Officer

NRx Pharmaceuticals (NASDAQ:NRXP) Reports Third Quarter and Year to Date 2024 Financial Results and Provides Business Update

NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) Reschedules Conference Call to Discuss Third Quarter and Year to Date 2024 Financial Results to November 18, 2024

$NRXP Leadership Updates

Live Leadership Updates

NRx Pharmaceuticals Announces the Election of Janet Rehnquist to its Board of Directors

NRx Pharmaceuticals Announces the Appointment of Carrie M. Carretta, PhD, APN-BC, AHN-BC, PMHNP, Senior Vice President of Clinical Development and Medical Affairs

NRx Pharmaceuticals Announces the Appointment of Stephen Willard, Chief Executive Officer and Director

Recent Analyst Ratings for
$NRXP

$NRXP
Financials

$NRXP
Insider Trading

$NRXP
Large Ownership Changes

$NRXP
Market Insights

$NRXP
SEC Filings

$NRXP
Press Releases

$NRXP
Leadership Updates